ABT : Summary for Abbott Laboratories Common Stoc - Yahoo Finance

U.S. Markets close in 5 hrs 5 mins

Abbott Laboratories (ABT)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.93+0.21 (+0.52%)
At close: 4:00PM EST
People also watch
ABBVBMYLLYJNJMRK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close40.72
Open40.75
Bid0.00 x
Ask0.00 x
Day's Range40.69 - 41.36
52 Week Range36.00 - 45.79
Volume9,533,780
Avg. Volume9,149,924
Market Cap70.45B
Beta1.49
PE Ratio (TTM)27.02
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.06 (2.59%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com2 days ago

    [$$] Credit Suisse Likes Expedia's Mash-Up of Brands

    Abbott Laboratories • ABT-NYSE Overweight • Price $40.74 on Jan. 9 by Barclays With the Jan. 4 close of Abbott’s acquisition of medical-device maker St. Jude Medical (STJ), we are updating our model to include both that purchase and recent divestitures (including Abbott medical optics and vascular units). For 2018, our EPS estimate has increased three cents, to $2.80, to reflect approximately 10% organic EPS growth and additional accretion from St. Jude of some 10 cents in earnings. In our view, Abbott shares have been dislocated by the noise around these deals and near deals, and we see this as a unique opportunity to buy a quality asset at a discount.

  • PR Newswire4 days ago

    Abbott Announces U.S. Launch and First Commercial Use of the New EnSite™ Precision Cardiac Mapping System

    ABBOTT PARK, Ill., Jan. 12, 2017 /PRNewswire/ -- Abbott (ABT) announced today the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments. Since the landmark clinical cases by Dr. Day, additional procedures supported by the new EnSite Precision cardiac mapping system have occurred in 12 states nationwide, supporting ablation procedures to treat complex arrhythmias. Abbott expects its new cardiac mapping technology to quickly become a new standard for use in treating patients experiencing arrhythmias from multiple origins in the heart.

  • Alinity ci-series Of Diagnostic Systems From Abbott Laboratories (ABT) Obtains CE Mark
    Insider Monkey5 days ago

    Alinity ci-series Of Diagnostic Systems From Abbott Laboratories (ABT) Obtains CE Mark

    Alinity, a family of next-generation clinical chemistry and immunoassay diagnostics from Abbott Laboratories (NYSE:ABT) is now being offered in Europe and other countries that distinguish the CE mark. The company has confirmed that the same have attained the CE mark. The new tools could come in handy in reducing the time spent running lab tests. […]